Sign In
Buy ALX
$250.02
+3.19 (+1.29%)
At Close: Jun 03, 2026
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
04:01pm, Tuesday, 06'th Aug 2024
- Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development - - Jaume Pons, Ph.D., and Sophia Randolph, M.D.
Alexander's (ALX) Beats Q2 FFO and Revenue Estimates
10:55am, Monday, 05'th Aug 2024
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $3.31 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.55 per share a year ago.
Alexander's Announces Second Quarter Financial Results
08:56am, Monday, 05'th Aug 2024
PARAMUS, N.J., Aug. 05, 2024 (GLOBE NEWSWIRE) -- ALEXANDER'S, INC. (New York Stock Exchange: ALX) filed its Form 10-Q for the quarter ended June 30, 2024 today and reported:
7 Potential Mousetrap REITs - High, Potentially Unsafe Yields
08:30am, Friday, 02'nd Aug 2024
From a fundamental standpoint, this may be a good time to invest in REITs with high yields. It's crucial to avoid mousetrap REITs with high dividend yields that may be unsustainable, as dividend cuts
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies tha
Alexander's Declares Quarterly $4.50 Dividend on Common Shares
01:32pm, Wednesday, 31'st Jul 2024
PARAMUS, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on Augus
SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies tha
Alexander's Announces Second Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call
02:53pm, Tuesday, 23'rd Jul 2024
PARAMUS, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2024 with the U.S. Se
Alexander's Inc.: Numerous Signs Of Distress
09:10am, Tuesday, 16'th Jul 2024
Office REITs have gained modestly this year, but face challenges due to the WFH trend and mounting defaults in commercial real estate loans. Alexanders, Inc. is a small-cap REIT with a portfolio of of
Three Office REITs To Sell With Weak Balance Sheets
08:00am, Thursday, 27'th Jun 2024
There will likely be a major sell-off in REITs in the next 2-5 years. Weak REITs with messy balance sheets, weak forecasts for FFO growth, unsafe dividends, and/or overvaluation are likely to suffer t
ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation
04:13am, Thursday, 27'th Jun 2024
ALX Oncology valuation has dropped below $500 million, presenting new studies at venues like ASCO, reaching a point of inflection. Evorpacept is the main focus, showing promising activity signals in g
ALX Resources Corp. Acquires Blackbird Project in Northern Saskatchewan
07:30am, Tuesday, 25'th Jun 2024
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce that it has acquired the Black
ALX Resources Corp. Receives Analytical Results from the Gibbons Creek Uranium Project, Athabasca Basin, Saskatchewan
07:30am, Thursday, 13'th Jun 2024
Vancouver, British Columbia--(Newsfile Corp. - June 13, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce the results of the 2024 winter
SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies tha
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
09:00am, Wednesday, 29'th May 2024
SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that
